FUJIFILM Diosynth Biotechnologies has integrated Cergentis’ proprietary Targeted Locus Amplification (TLA) technology into our Apollo™ X cell-line development as a powerful tool for targeted, complete sequencing of transgenes and integration sites. TLA identifies all transgene integration sites and detects all single-nucleotide variants (SNVs) and structural variants in an integrated transgene sequence.
This webinar will:
– Pinpoint key Apollo™ X features;
– Introduce Cergentis’ proprietary Targeted Locus Amplification (TLA) technology for transgene & integration site characterization;
– Present how the TLA technology allows FUJIFILM Diosynth Biotechnologies to support rapid genetic characterization of clonal cell lines during Apollo™ X cell-line development and clone selection. This includes early confirmation of recombinant-gene integrity and identification and elimination of clones that produce aberrant protein products.